Neoadjuvant sintilimab combined with chemotherapy in patients with resectable esophageal squamous cell carcinoma (ESCC): Preliminary results from a phase II study.

被引：0
|
作者：
Guo, Jincheng [1 ]
Qiao, Chengrui [1 ]
Lu, Jiabin [1 ]
Yang, Shiqing [1 ]
Zhang, Boyi [1 ]
机构：
[1] Henan Univ Technol, Affiliated Hosp 1, Jiaozuo, Henan, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16008
引用
收藏
页码：E16008 / E16008
页数：1
相关论文
共 50 条
  • [21] Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study
    Liu, Jun
    Li, Jingpei
    Lin, Wanli
    Shao, Di
    Depypere, Lieven
    Zhang, Zhifeng
    Li, Zhuoyi
    Cui, Fei
    Du, Zesen
    Zeng, Yuan
    Jiang, Shunjun
    He, Ping
    Gu, Xia
    Chen, Huai
    Zhang, Hai
    Lin, Xiaowei
    Huang, Haoda
    Lv, Wenqiang
    Cai, Weiming
    Liang, Wenhua
    Liang, Hengrui
    Jiang, Wenxi
    Wang, Wei
    Xu, Ke
    Cai, Weipeng
    Wu, Kui
    Lerut, Toni
    Fu, Junhui
    He, Jianxing
    INTERNATIONAL JOURNAL OF CANCER, 2022, 151 (01) : 128 - 137
  • [22] The efficacy and safety of neoadjuvant sintilimab combined with chemotherapy in elderly patients with locally advanced esophageal squamous cell carcinoma.
    Lv, Huilai
    Huang, Chao
    Li, Jiachen
    Zhang, Fan
    Gai, Chunyue
    Liu, Zhao
    Xu, Shi
    Wang, Mingbo
    Li, Zhenhua
    Tian, Ziqiang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 378 - 378
  • [23] Tislelizumab in combination with chemotherapy for the treatment of Chinese patients (pts) with esophageal squamous cell carcinoma (ESCC): Results from one cohort of an ongoing phase 2 study.
    Xu, Nong
    Yuan, Xianglin
    Wang, Buhai
    Bai, Yu-Xian
    Li, En Xiao
    Li, Yanyan
    Wang, Huanli
    Xu, Jianming
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [24] Preoperative pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma (ESCC): The phase II Keystone-001 trial
    Jiang, H.
    Shang, X.
    Xie, Y.
    Zhao, G.
    Zhang, C.
    Zhang, W.
    Liu, L.
    Li, R.
    Yue, J.
    Chen, C.
    Duan, X.
    Ma, Z.
    Sun, Y.
    Yu, J.
    Ren, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S872 - S873
  • [25] Neoadjuvant PD-1 blockade combined with chemotherapy for patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC): A real world data analysis
    Lv, H.
    Tian, Y.
    Huang, C.
    Sun, B.
    Gai, C.
    Li, Z.
    Tian, Z.
    ANNALS OF ONCOLOGY, 2021, 32 : S1423 - S1423
  • [26] The efficacy and safety of neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced lymph node-positive esophageal squamous cell carcinoma: A real world study
    Ye, Peng
    Rusidanmu, Aizemaiti
    Lin, Shuang
    Zhou, Kun
    Wu, Xuhui
    Huang, Bin
    Wu, Gongzhi
    Peng, Congxiong
    Peng, Xuyang
    Ding, Jianyang
    Huang, Mingjiang
    Yu, Huanming
    Zhi, Shengxu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Neoadjuvant anlotinib combined with penpulimab for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II trial.
    Chen, Yueyun
    Ding, Zhen-Yu
    Yuan, Yong
    Yang, Yu-Shang
    Lin, Zhen
    Tian, Jiangfang
    Liu, Ting
    Yue, Zheng
    Shi, Hua-Shan
    Hu, Yang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 352 - 352
  • [28] Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma
    Yang, Weixiong
    Xing, Xiangbin
    Yeung, Sai-Ching Jim
    Wang, Siyu
    Chen, Wenfang
    Bao, Yong
    Wang, Fang
    Feng, Shiting
    Peng, Fang
    Wang, Xiaoyan
    Chen, Shuling
    He, Minghui
    Zhang, Ning
    Wang, Honglei
    Zeng, Bo
    Liu, Zhenguo
    Kidane, Biniam
    Seder, Christopher W.
    Koyanagi, Kazuo
    Shargall, Yaron
    Luo, Honghe
    Peng, Sui
    Cheng, Chao
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (01)
  • [29] A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
    Chu, L.
    Liang, F.
    Zhang, J.
    Deng, J.
    Chen, Y.
    Liu, Q.
    Ai, D.
    Zhu, Z.
    Zhao, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [30] Neoadjuvant chemoradiotherapy (nCRT) combined with sequential tislelizumab for resectable esophageal squamous cell carcinoma (ESCC): Preliminary results of a single-arm, open-label phase Ib trial (CRIS)
    Jiang, Youhua
    Qiu, Guoqin
    Li, Jianqiang
    Wang, Jiangfeng
    Wang, Changchun
    Wu, Jie
    Cheng, Lei
    Zheng, Yuanda
    Ruan, Rongwei
    Song, Ge
    Ye, Xuemei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345